Advertisement
Advertisement
LYEL
Lyell Immunopharma, Inc. Common Stock
14.71
USDSponsored
+0.50
+3.52%
Aug 07, 15:59 UTC -4
Closed
After-Market
14.73
+0.02
+0.14%
LYEL Earnings Reports
Positive Surprise Ratio
LYEL beat 15 of 20 last estimates.
75%
Next Report
Tomorrow
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
$3.91K
/-$2.06
Implied change from Q1 26 (Revenue/ EPS)
+95.30%
/+87.27%
Implied change from Q2 25 (Revenue/ EPS)
-51.17%
/-28.72%
Lyell Immunopharma, Inc. Common Stock earnings per share and revenue
On May 06, 2026, LYEL reported earnings of -1.10 USD per share (EPS) for Q1 26, beating the estimate of -2.41 USD, resulting in a 54.40% surprise. Revenue reached 2.00 thousand, compared to an expected 4.49 thousand, with a -55.44% difference. The market reacted with a -3.79% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -2.06 USD, with revenue projected to reach 3.91 thousand USD, implying an increase of 87.27% EPS, and increase of 95.30% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Ardelyx, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-18.85%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.74
Actual
$1.92
Surprise
+9.75%
Cronos Group Inc. Common Share
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.00
Actual
$0.03
Surprise
0.00%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.36
Actual
$0.31
Surprise
-14.62%
Relmada Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+45.95%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.35
Actual
-$0.71
Surprise
-98.88%
Avita Medical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.29
Actual
-$0.25
Surprise
+14.50%
electroCore, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.43
Actual
-$0.33
Surprise
+23.40%
Definium Therapeutics, Inc. Common Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.55
Actual
-$1.44
Surprise
-158.25%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.36
Actual
-$0.39
Surprise
-5.95%
FAQ
What were Lyell Immunopharma, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Lyell Immunopharma, Inc. Common Stock reported EPS of -$1.10, beating estimates by 54.4%, and revenue of $2.00K, -55.44% below expectations.
How did the market react to Lyell Immunopharma, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -3.79%, changed from $20.85 before the earnings release to $20.06 the day after.
When is Lyell Immunopharma, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for Lyell Immunopharma, Inc. Common Stock's next earnings report?
Based on --
analysts, Lyell Immunopharma, Inc. Common Stock is expected to report EPS of -$2.06 and revenue of $3.91K for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement